| Bioactivity | RET-IN-22 (compound 17b) is a potent, selective and orally active RET inhibitor with an IC50 of 20.9 nM and 18.3 nM for wild-type RET and RET-V804M, respectively. RET-IN-22 shows highly selective profile to most kinases, especially to EGFR and VEGFR2. RET-IN-22 has anticancer effects[1]. |
| Target | IC50: 20.9 nM (wild-type RET) and 18.3 nM (RET-V804M) |
| Name | RET-IN-22 |
| CAS | 2918281-79-3 |
| Formula | C29H31F3N6O4 |
| Molar Mass | 584.59 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kaifu Wu, et al. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors. Eur J Med Chem. 2023 May 5;251:115237. |
RET-IN-22
CAS: 2918281-79-3 F: C29H31F3N6O4 W: 584.59
RET-IN-22 (compound 17b) is a potent, selective and orally active RET inhibitor with an IC50 of 20.9 nM and 18.3 nM for
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.